Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin Sells 3,348 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 3,348 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $20.12, for a total value of $67,361.76. Following the completion of the sale, the chief accounting officer now directly owns 63,654 shares of the company’s stock, valued at $1,280,718.48. The trade was a 5.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Sandra Calvin also recently made the following trade(s):

• On Wednesday, January 22nd, Sandra Calvin sold 925 shares of Travere Therapeutics stock. The shares were sold at an average price of $18.94, for a total value of $17,519.50.
• On Thursday, December 26th, Sandra Calvin sold 15,000 shares of Travere Therapeutics stock. The shares were sold at an average price of $17.22, for a total value of $258,300.00.
• On Monday, November 25th, Sandra Calvin sold 12,090 shares of Travere Therapeutics stock. The shares were sold at an average price of $18.30, for a total transaction of $221,247.00.

Travere Therapeutics Price Performance

Shares of TVTX opened at $21.10 on Wednesday. The stock has a 50 day moving average of $18.69 and a 200 day moving average of $15.47. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. Travere Therapeutics, Inc. has a 12 month low of $5.12 and a 12 month high of $21.56.

Institutional Investors Weigh In On Travere Therapeutics

Several large investors have recently made changes to their positions in TVTX. Emerald Advisers LLC boosted its holdings in shares of Travere Therapeutics by 19.8% in the 3rd quarter. Emerald Advisers LLC now owns 1,960,659 shares of the company’s stock worth $27,430,000 after buying an additional 323,513 shares during the last quarter. Finepoint Capital LP raised its position in Travere Therapeutics by 0.3% in the third quarter. Finepoint Capital LP now owns 1,782,267 shares of the company’s stock worth $24,934,000 after acquiring an additional 5,539 shares during the period. Geode Capital Management LLC boosted its stake in Travere Therapeutics by 3.9% in the third quarter. Geode Capital Management LLC now owns 1,731,045 shares of the company’s stock valued at $24,222,000 after acquiring an additional 64,744 shares during the last quarter. Emerald Mutual Fund Advisers Trust grew its position in shares of Travere Therapeutics by 26.0% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 1,185,709 shares of the company’s stock valued at $16,588,000 after acquiring an additional 244,444 shares during the period. Finally, Parkman Healthcare Partners LLC grew its position in shares of Travere Therapeutics by 12.0% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,086,067 shares of the company’s stock valued at $15,194,000 after acquiring an additional 116,175 shares during the period.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Wedbush upped their price objective on shares of Travere Therapeutics from $17.00 to $25.00 and gave the stock an “outperform” rating in a report on Wednesday, October 9th. Guggenheim raised their price target on shares of Travere Therapeutics from $23.00 to $41.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. HC Wainwright lifted their price target on Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a research note on Wednesday, January 15th. Scotiabank increased their price objective on Travere Therapeutics from $23.00 to $27.00 and gave the stock a “sector outperform” rating in a research note on Friday, November 1st. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $20.00 target price on shares of Travere Therapeutics in a research report on Tuesday, October 8th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, Travere Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $24.00.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.